DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus

(2022) Nasr E. Nasr et al.   ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

A review upon medicinal perspective and designing rationale of DPP-4 inhibitors

(2021) Shubham Kumar et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms

(2021) Elena Massimino et al.   Cells

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis

(2021) Yuka Shiheido-Watanabe et al.   JACC-Basic to Translational Science

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

(2020) Matthew P. Gilbert et al.   Frontiers in Endocrinology

Drug Design of GLP-1 Receptor Agonists: Importance of In silico Methods

(2020) Smriti Sharma et al.   CURRENT PHARMACEUTICAL DESIGN

The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes

(2020) Daniel V. O'Hara et al.   DIABETES OBESITY & METABOLISM

Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus

(2019) Giorgio Sesti et al.   ACTA DIABETOLOGICA

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

(2019) Carolyn F. Deacon   Frontiers in Endocrinology

The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect

(2019) Konstantinos Makrilakis   International Journal of Environmental Research and Public Health

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs

(2019) Jianqiang Zhang et al.   Frontiers in Immunology

Clinical Use of DPP-4 Inhibitors

(2019) Baptist Gallwitz   Frontiers in Endocrinology

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis

(2019) Yue Fei et al.   Cardiovascular Diabetology

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

(2019) David R Matthews et al.   LANCET

Surrogating and redirection of pyrazolo[1,5- a ]pyrimidin-7(4 H )-one core, a novel class of potent and selective DPP-4 inhibitors

(2018) Xinxian Deng et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?Novelty and Significance

(2018) Milton Packer   CIRCULATION RESEARCH

Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection

(2018) Katarina Tomovic et al.   MEDICINAL RESEARCH REVIEWS

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis

(2018) Lana C. Pinto et al.   Scientific Reports

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea

(2016) G. Lozano-Ortega et al.   CURRENT MEDICAL RESEARCH AND OPINION

Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis

(2016) Edoardo Mannucci et al.   DIABETES CARE

Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes

(2016) Xueying Tan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes

(2016) Suetonia C. Palmer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study

(2016) Dimitrios Baltzis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors

(2016) Maria Rosaria Rizzo et al.   Journal of the American Medical Directors Association

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

(2016) Sung-Ho Kim et al.   Diabetes & Metabolism Journal

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

(2016) Charles E. Grimshaw et al.   PLoS One

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

(2016) Heidi Storgaard et al.   PLoS One

Saxagliptin: A Review in Type 2 Diabetes

(2015) Sohita Dhillon   DRUGS

Omarigliptin: First Global Approval

(2015) Celeste B. Burness   DRUGS

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability

(2015) Hiroyuki Ito et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

(2014) Nayyar Iqbal et al.   Cardiovascular Diabetology

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials

(2014) George Grunberger   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

DPP-4 inhibitors: pharmacological differences and their clinical implications

(2014) Antonio Ceriello et al.   Expert Opinion On Drug Safety

DPP-4 inhibitors: focus on safety

(2014) Sri Harsha Tella et al.   Expert Opinion On Drug Safety

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

(2014) N Waugh et al.   HEALTH TECHNOLOGY ASSESSMENT

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sitagliptin Use in Patients With Diabetes and Heart Failure

(2014) Daniala L. Weir et al.   JACC-Heart Failure

GLP-1 receptor agonists: a review of head-to-head clinical studies

(2014) Jennifer M. Trujillo et al.   Therapeutic Advances in Endocrinology and Metabolism

Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and "Isoglycemic" Intravenous Glucose

(2013) I. Vardarli et al.   DIABETES

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

(2013) D. Anz et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

(2013) J. A. Hirst et al.   DIABETOLOGIA

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Pharmacology, Efficacy, and Safety of Linagliptin for the Treatment of Type 2 Diabetes Mellitus

(2012) Joshua J Neumiller   ANNALS OF PHARMACOTHERAPY

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

(2012) Tomohiro Yoshida et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

(2012) Yan-Ling He   CLINICAL PHARMACOKINETICS

Cardiovascular effects of the DPP-4 inhibitors

(2012) Tessey Jose et al.   Diabetes & Vascular Disease Research

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

(2012) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Alogliptin benzoate for the treatment of type 2 diabetes

(2012) Marc Rendell et al.   EXPERT OPINION ON PHARMACOTHERAPY

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

(2012) Johan Farngren et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

(2012) Noriko Satoh-Asahara et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults

(2011) Christian Friedrich et al.   CLINICAL DRUG INVESTIGATION

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

(2011) A.J. Scheen   DIABETES & METABOLISM

Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of

(2011) D. Giugliano et al.   DIABETES CARE

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors

(2011) D. Dicker   DIABETES CARE

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

(2011) E. Bosi et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

A review of gliptins in 2011

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

(2011) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes

(2011) Chetan Karyekar et al.   POSTGRADUATE MEDICINE

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

(2011) Zubair Shah et al.   VASCULAR PHARMACOLOGY

Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1

(2011) Gian Paolo Fadini et al.   VASCULAR PHARMACOLOGY

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

(2010) M. Ligueros-Saylan et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

(2010) C. F. Deacon   DIABETES OBESITY & METABOLISM

DPP-4 inhibitors: What may be the clinical differentiators?

(2010) John Gerich   DIABETES RESEARCH AND CLINICAL PRACTICE

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects

(2010) Ulrike Graefe-Mody et al.   Drug Metabolism and Pharmacokinetics

Sitagliptin

(2010) Sohita Dhillon   DRUGS

Molecular mechanisms underlying nutrient-stimulated incretin secretion

(2010) Helen E. Parker et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients

(2010) G. Derosa et al.   HORMONE AND METABOLIC RESEARCH

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

(2010) Annis Marney et al.   HYPERTENSION

Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals

(2010) JosephA Davis et al.   INDIAN JOURNAL OF PHARMACOLOGY

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

(2010) Mathias Nicolaus et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Addition of incretin therapy to metformin in type 2 diabetes

(2010) André J Scheen et al.   LANCET

A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

(2010) Walid K.H. Fakhoury et al.   PHARMACOLOGY

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2010) Joshua J Neumiller et al.   PHARMACOTHERAPY

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Saxagliptin for type 2 diabetes

(2010) Chacra   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

(2009) Georgia Argyrakopoulou et al.   ADVANCES IN THERAPY

Drug evaluation: Vildagliptin-metformin single-tablet combination

(2009) Abd A. Tahrani et al.   ADVANCES IN THERAPY

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

(2009) Abd A. Tahrani et al.   ADVANCES IN THERAPY

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes

(2009) Shrikanth H. Havale et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats

(2009) Holger Fuchs et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

(2009) Kyoung Soo Lim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

(2009) J. Rosenstock et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

(2009) R. A. DeFronzo et al.   DIABETES CARE

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

(2009) M. Jadzinsky et al.   DIABETES OBESITY & METABOLISM

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes

(2009) J. Cuthbertson et al.   DIABETIC MEDICINE

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)

(2009) A. J. Scheen et al.   DIABETIC MEDICINE

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

(2009) Carolyn F Deacon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Vildagliptin in clinical practice: a review of literature

(2009) Moulinath Banerjee et al.   EXPERT OPINION ON PHARMACOTHERAPY

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

(2009) A. R. Chacra et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin

(2009) D. Hamish Wright et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

(2009) Aziz Karim et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

(2009) Raffaele Marfella et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

(2009) Joshua J. Neumiller   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

(2009) Giuseppe Derosa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

DPP-4 Inhibitors in Clinical Practice

(2009) Anna I. Palalau et al.   POSTGRADUATE MEDICINE

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes

(2008) J.-F. Gautier et al.   DIABETES & METABOLISM

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

(2008) B. Schwarz et al.   DIABETES OBESITY & METABOLISM

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

New Drugs for Type 2 Diabetes Mellitus

(2008) Andrew J Krentz et al.   DRUGS

Janumet™: a combination product suitable for use in patients with Type 2 diabetes

(2008) Jonathan Kent Reynolds et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin

(2008) B. Göke et al.   HORMONE AND METABOLIC RESEARCH

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients

(2008) Michael Boschmann et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers

(2008) Pei Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation

(2008) William J. Metzler et al.   PROTEIN SCIENCE

Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia

(2007) Andrea Mari et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM